Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.

The aim of combination drug treatment in cancer therapy is to improve response rate and to decrease the probability of the development of drug resistance. Preferably, drug combinations are synergistic rather than additive, and, ideally, drug combinations work synergistically only in cancer cells and...

Full description

Bibliographic Details
Main Authors: Joost C M Uitdehaag, Jeroen A D M de Roos, Antoon M van Doornmalen, Martine B W Prinsen, Jill A P Spijkers-Hagelstein, Judith R F de Vetter, Jos de Man, Rogier C Buijsman, Guido J R Zaman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4446296?pdf=render

Internet

http://europepmc.org/articles/PMC4446296?pdf=render

Similar Items